<DOC>
	<DOCNO>NCT00818038</DOCNO>
	<brief_summary>The primary objective study measure change bladder function measure Urogenital Distress Inventory ( UDI ) -6 compare baseline 6 month Tysabri treatment . Secondary objective ( ) measure change baseline 6 month Tysabri treatment number urinary incontinence episode per participant per week , ( ii ) measure change baseline 6 month Tysabri treatment number micturition per participant per day , ( iii ) measure change The North American Research Committee Multiple Sclerosis ( NARCOMS ) bladder/bowel subscale ( PSB ) score baseline 6 month Tysabri treatment ( iv ) measure change Incontinence Impact Questionnaire ( IIQ ) -7 score baseline 6 month Tysabri treatment .</brief_summary>
	<brief_title>A Proof Concept Study Evaluate Effectiveness Tysabri Relapsing Remitting Multiple Sclerosis ( RRMS ) Patient Bladder Function</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Key Participants eligible screen study follow criterion meet : Patient must meet prescribe criterion TYSABRI® eligible TOUCH™ program . If utilizing medication symptom bladder dysfunction ( incontinence , urgency etc ) , subject need remain stable dose medication ( ) least one month prior duration study . If utilizing medication affect urinary output ( e.g . anticholinergic , diuretic , etc . ) , subject need remain stable dose medication ( ) least one month prior study entry duration study . Able provide write informed consent . Patient must willing maintain current hydration habit caffeine intake duration study . Participants select enrollment follow criterion meet : Screening Visit urinary incontinence define : Greater equal 3 incontinence episode per week great equal 8 micturition per day ( mean number ) . Screening Visit score UDI6 equal 6 . Screening Visit EDSS 0 6.5 Key Candidates exclude study screen follow exclusion criterion exist : Primary progressive , secondary progressive , progressive relapse MS. Primary progressive , secondary progressive progressive relapse multiple sclerosis define Lublin Reingold ( Lublin Reingold , 1996 ) EDSS &gt; 6.5 . Current previous history Progressive Multifocal Leukencephalopathy ( PML ) . A clinically significant infectious illness ( e.g. , cellulitis , abscess , pneumonia , septicemia ) within 30 day . History recurrent chronic urinary tract infection urinary tract infection within precede 30 day prior Week 0 ( diagnosis base clinical history Screening Visit urinalysis urine culture ) . Patients indwell foley catheter suprapubic catheter . Patients history symptomatic benign prostatic hyperplasia ( BPH ) history prostate cancer . History , abnormal laboratory result indicative , significant cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , gastrointestinal , dermatologic , psychiatric , renal , and/or major disease , , opinion investigator , would preclude administration natalizumab duration study . Subject history malignancy within past 2 year , exception basal cell carcinoma treat . History severe allergic anaphylactic reaction know drug hypersensitivity . Any prior treatment follow medication : Natalizumab ( TYSABRI® ) Nursing mother , pregnant woman , woman plan become pregnant study . Any reason , opinion Investigator and/or Sponsor , subject determine unsuitable enrollment study . Unwillingness inability comply requirement protocol include presence condition ( physical , mental , social ) likely affect subject 's ability comply study protocol . History alcohol drug abuse within 2 year prior randomization . Female subject postmenopausal least 1 year , surgically sterile , willing use medically acceptable method birth control study . The rhythm method use sole method contraception . Participants determine screen failure follow criterion apply : Abnormal blood test , perform screen visit , exceed limit define : 1 . ALT/ SGPT , AST/ SGOT three time upper limit normal ( i.e. , 3xULN ) . 2 . Total white blood cell ( WBC ) count less 2,300/mm3 . 3 . Platelet count less 100,000/mm3 . 4 . Creatinine 2xULN . Screening Visit urinary incontinence define less 3 incontinence episode per week le 8 micturition per day ( mean number ) . Screening Visit score UDI6 le 6 . Screening Visit EDSS 6.5 . NOTE : Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>RRMS</keyword>
	<keyword>Relapsing Remitting</keyword>
	<keyword>MS</keyword>
</DOC>